{rfName}

Indexed in

License and use

Icono OpenAccess

Altmetrics

Grant support

Mar Guasp is a recipient of Juan Rodes grant (JR23/00030) from the Instituto de Salud Carlos III, co-financed by Fondo Social Europeo Plus.

Share

August 18, 2024
Publications
>
Article

CD19-Directed CAR T-Cells in a Patient With Refractory MOGAD

Publicated to:Neurology-Neuroimmunology & Neuroinflammation. 11 (5): e200292- - 2024-09-01 11(5), DOI: 10.1212/NXI.0000000000200292

Authors: Cabrera-Maqueda, Jose Maria; Sepulveda, Maria; Garcia, Raquel Ruiz; Munoz-Sanchez, Guillermo; Martinez-Cibrian, Nuria; Ortiz-Maldonado, Valentin; Lorca-Arce, Daniel; Guasp, Mar; Llufriu, Sara; Martinez-Hernandez, Eugenia; Armangue, Thais; Fonseca, Elianet G; Alba-Isasi, Maria Teresa; Delgado, Julio; Dalmau, Josep; Juan, Manel; Saiz, Albert; Blanco, Yolanda

Affiliations

Ctr Invest Biomed Red Canc CIBERONC, Barcelona, Spain - Author
Fundacio Recerca Clin Barcelona Inst Invest Biomed, Neuroimmunol Program, Barcelona, Spain - Author
Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain - Author
Hosp Clin Barcelona, Neuroimmunol & Multiple Sclerosis Unit, Serv Neurol, Barcelona, Spain - Author
Inst Invest Biomed August Pi i Sunyer IDIBAPS, Pediat Neuroimmunol Unit, Barcelona, Spain - Author
Joint Platform Immunotherapy St Joan de Deu Hosp C, Barcelona, Spain - Author
Univ Barcelona, Barcelona, Spain - Author
Univ Barcelona, Caixa Res Inst, Barcelona, Spain - Author
Univ Barcelona, Hosp Clin Barcelona, Inst Invest Biomed August Pi Sunyer i, Dept Immunol, Barcelona, Spain - Author
Univ Barcelona, St Joan Deu SJD Childrens Hosp, Dept Neurol, Barcelona, Spain - Author
See more

Abstract

ObjectivesIn MOG antibody-associated disease (MOGAD), relapse prevention and the treatment approach to refractory symptoms are unknown. We report a patient with refractory MOGAD treated with CD19-directed CAR T-cells.MethodsCD19-directed CAR T-cells (ARI-0001) were produced in-house by lentiviral transduction of autologous fresh leukapheresis and infused after a conventional lymphodepleting regimen.ResultsA 18-year-old man developed 2 episodes of myelitis associated with serum MOG-IgG, which were followed by 6 episodes of left optic neuritis (ON) and sustained the presence of MOG-IgG over 6 years despite multiple immunotherapies. After the sixth episode of ON, accompanied by severe residual visual deficits, CAR T-cell treatment was provided without complications. Follow-up of cell counts showed complete depletion of CD19+ B cells at day +7; reconstituted B cells at day +141 showing a na & iuml;ve B-cell phenotype, and low or absent memory B cells and plasmablasts for 1 year. MOG-IgG titers have remained undetectable since CAR T-cell infusion. The patient had an early episode of left ON at day +29, when MOG-IgG was already negative, and since then he has remained free of relapses without immunotherapy for 1 year.DiscussionThis clinical case shows that CD19-directed CAR T-cell therapy is well-tolerated and is a potential treatment for patients with refractory MOGAD.Classification of EvidenceThis provides Class IV evidence. It is a single observational study without controls.

Keywords

AdolescentAdoptive immunotherapyAdultAntigens, cd19ArticleCase reportCd19 antigenCd19 molecule, humanChimeric antigen receptorChimeric antigen receptor t-cell immunotherapyClinical articleDisease courseFollow upFollow-up studiesHumanHuman cellHumansImmunoglobulinImmunologyImmunotherapyImmunotherapy, adoptiveLeukapheresisMaleMemory b lymphocyteMog protein, humanMycophenolate mofetilMyelin oligodendrocyte glycoproteinMyelin oligodendrocyte glycoprotein antibody associated diseaseMyelin-oligodendrocyte glycoproteinMyelitisOptic neuritisPhenotypePlasmablastPrednisoneReceptors, chimeric antigenRelapseRituximabSecondary preventionT lymphocyteT-lymphocytesTherapyTreatment outcomeVarnimcabtagene autoleucelVisual disorderYoung adult

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Neurology-Neuroimmunology & Neuroinflammation due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2024 there are still no calculated indicators, but in 2023, it was in position 19/310, thus managing to position itself as a Q1 (Primer Cuartil), in the category Neurosciences. Notably, the journal is positioned above the 90th percentile.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2025-07-16:

  • WoS: 4
  • Scopus: 2
  • Europe PMC: 2

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-16:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 13.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 24 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 0.75.
  • The number of mentions on the social network Facebook: 1 (Altmetric).
  • The number of mentions on the social network X (formerly Twitter): 1 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Cabrera Maqueda, Jose Maria) and Last Author (Blanco Morgado, Yolanda).

the author responsible for correspondence tasks has been Blanco Morgado, Yolanda.